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patients, riociguat increased the proportion fulfilling criteria defining a positive 
response to therapy.
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Objectives: A pilot test to assess patient-centered outcomes in daily manage-
ment of coronary artery disease at cardiology clinics in Thailand. MethOds: A 
Delphi method was used for development of PRO questionnaire assessing along 
with ivabradine treatment from randomly selected CSAP patients under the Health 
Authorities’ pharmacovigilance monitoring program. A 15-items short-form health 
survey with 5 response choices adopted with permission from validity-tested PRO 
used in medical outcomes study in Thai patients, four health dimensions included 
general, physical, social function role limiting and mental health dimensions with 
1, 6, 5 and 3 items each respectively. Standardized scoring was calculated with 
the lowest(0) to highest(100). Field tests among healthy volunteers performed.The 
reliability test employed inter-item and intra-item consistency using Cronbach’s 
alpha coefficient. All 15 items of survey were evaluated at initiation and after 
four months clinical intervention. The treatment acceptability was further 
assessed from patient interviews. Results: Of 162 patients randomly selected 
for PRO evaluation, 85(53%) was men, all patients mean(SD) age of 67.3(11.7) years 
whom 97(59.5%)was > 65 years, 9(5.5%) was smokers and 81(49.7%) had a Body 
Mass Index ≥ 25 kg/m2. Forty-three (26.4%) of patients had previous intervention 
and 63(39%) had heart failure(HF). The internal consistency of the score for all 
15 items, for physical, social function role limiting and mental health dimen-
sions, reflected Chronbach’s alpha coefficient of 0.888, 0.771, 0.702 and 0.807 at 
baseline. After 4-month, Cronbach’s alpha coefficient were of 0.735, 0.715, 0.661 
and 0.519. All mean scores(SD) of these four health dimensions, were signifi-
cantly improved from 47.59(11.50) to 54.91(9.45), from 50.33(12.11) to 54.91(10.42), 
from 39.53(10.35) to 52.68(10.32) and from 45.88(17.08) to 54.88(18.49) respectively 
(P< 0.001). cOnclusiOns: This pilot development confirms reliability of 15-items 
short-form health survey, score is consistent overtime. Thai CSAP patients who 
were prescribed ivabradine reported a highly significant improvement in qual-
ity of life including all health dimensions general, physical, social function role 
limiting and mental health. Patient-reported outcomes questionnaires could be 
recommended alongside clinical treatment.
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Objectives: European guidelines support LDL-C goals based on an individual’s 
absolute cardiovascular (CV) risk and have established a goal of < 70 mg/dL in very 
high CV risk patients. The objective of this study was to estimate the proportion of 
individuals that attain these goals and assess the determinants of any observed 
variation. MethOds: Patients in The Health Improvement Network (THIN) UK 
general practice database with an LDL-C measurement during 2011 and at very 
high risk of CV risk events were identified and further categorized as recent acute 
coronary syndrome (ACS, within 6 months pre LDL-C measurement), prior coronary 
events, stroke, and peripheral vascular disease (PVD). Lipid-lowering therapy (LLT) 
was categorized as high-potency statin, standard-potency statin, non-statin LLT, 
and no LLT. Results: In total, 25,535 patients met the inclusion criterion. Median 
(inter-quartile range [IQR]) age was 71 (62 to 79) years, 63.5% were male, and median 
(IQR) LDL-C was 108 (83 to 139) mg/dL. Across the total cohort, 6.3%, 61.3%, 17.8%, and 
14.6% had evidence of recent ACS, prior coronary events, stroke, and PVD. Patients 
with LDL-C < 70 mg/dL within these categories were 18.9%, 13.5%, 14.5%, and 11.4%. 
Across the total cohort, 16.0%, 52.5%, 0.5%, and 31.0% were on high-potency statin, 
standard-potency statin, non-statin LLT, and no LLT. Patients with LDL-C < 70 mg/
dL within these LLT categories were 18.3%, 15.4%, 11.6%, and 8.5%. cOnclusiOns: 
In a large, contemporary cohort of very high CV risk patients, few achieved the 
optimal LDL-C goal of < 70 mg/dL. One third were not on any LLT, < 20% were on 
high-potency statin, and > 80% of those receiving high-potency statins were not at 
LDL-C goal. These data suggest the need for ongoing efforts to improve prescribing 
of appropriate LLT as well as identifying new therapies to improve goal attainment 
among very high CV risk patients.
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Objectives: Venous thromboembolism (VTE) is a relatively common post-operative 
complication in cancer patients associated with high mortality rates. Gynae-oncology 
patients are predisposed to developing VTE due to the presence of a number of high 
risk factors. Current thromboprophylactic protocols for LMWH dosage and duration 
may be insufficient as a significant percentage of VTEs in gynae-oncology patients 
occur despite LMWH prophylaxis. The aim of this study is to investigate the antico-
agulant (anti-Xa) activity of Tinzaparin prophylaxis in the immediate post-operative 
period in gynae-oncology patients. MethOds: All patients attending St. James’s 
recommended therapeutic strategies and clinical outcomes as a function of the 
therapeutic strategies in a real world setting. MethOds: An observational retro-
spective cohort analysis based on 4 Local Health Units administrative databases 
was conducted. High CV risk patients who filled at least one prescription for high 
dosages statins between January 1, 2007-December 31, 2007 (enrolment period) 
were included. Patients were followed-up for 24 months. Patients were defined as 
adherent if they had > 80% of follow up period covered by drugs dispensation. To 
correct for potential confounders, a multivariable proportional hazards Cox regres-
sion model considering age, gender, type of statin, adherence to treatment and 
stay on treatment was assessed. Stay on treatment was defined as no switch or 
down titration during the follow up period. Results: Among 36,327 (3% of the 
population) high CV risk patients, Rosuvastatin 40mg (R40) and Atorvastatin 80mg 
(A80) were not used (0.1% each treatment); 625 (2%) patients used R20 and 908 (2%) 
A40. Stay on treatment was similar across treatments: 61% for R20 and 60% for A40 
(p= 0.583). 2.6 (1.7-3.5) CV events per 100 patients/year for R20 and 4.4 (3.4-5.4) for 
A40 were observed (p= 0.014). At the multivariable Cox regression analysis, risk of 
CV event was lower for R20, as compared to A40 (HR= 0.60, 95%CI 0.39-0.91, p= 0.017). 
Other statistically significant covariates were adherence (HR= 0.50, 95%CI 0.29-0.87, 
p= 0.015) and stay on treatment (HR= 0.58, 95%CI 0.40-0.85, p= 0.006). cOnclusiOns: 
Despite guidelines recommendations, high dosages statins are poorly used in real 
practice. Stay on treatment was similar among those treated with R20 and A40, even 
though R20 showed a lower incidence of cardiovascular events.
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Objectives: This analysis estimates the impact of switching from rosuvastatin 
to atorvastatin on cardiovascular (CV) events. MethOds: Using the Archimedes 
model, a discrete-event simulation, we evaluated a simulated population of 50,038 
patients aged 45–70 years with dyslipidemia and adherent to rosuvastatin. The 
virtual population was created based on matched biomarker profiles of patients 
in the National Health and Nutrition Examination Survey (NHANES). Statin treat-
ment models were based on data from published studies, including STELLAR, 
JUPITER, CARDS, ASCOT, and TNT. Patients were started on a rosuvastatin dose 
based on their LDL-C and ATP-III goal. Treatment prevalence was calibrated to 
match distributions of statin use observed in U.S. pharmacy claims data. In the 
experimental arm, patients switched to twice the mg atorvastatin dose as their 
rosuvastatin dose at their first follow-up visit (no switching occurred in the con-
trol arm). Patients were monitored for 5 years, during which time they received 
regular visits, with the opportunity to increase their dosage if they were above 
their LDL-C goal. Rate of first occurrence of MI, stroke, or CV death (MACE) for 
each arm was estimated. Results: After 5 years, when all patients switched to 
atorvastatin, 4.8% fewer patients reached goal, and mean LDL-C increased by 7.1 
mg/dL. The 5-year relative risk of MACE was 1.117 (95% CI 1.098–1.135), and the 
number needed to harm (NNH) to incur one additional MACE was 262, favoring 
rosuvastatin. For diabetics, the relative risk of MACE was 1.128 (95% CI 1.096–1.159), 
and the NNH to incur one additional MACE was 195, indicating greater risk for dia-
betics. The results were insensitive to assumptions of adherence rates and LDL-C 
goal values. cOnclusiOns: In this simulation, switching from rosuvastatin to 
atorvastatin led to fewer patients attaining LDL-C goal, higher mean LDL-C values, 
and greater risk of MACE over 5 years.
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Objectives: Indications for PAH medications vary between countries, and prod-
ucts may have restricted reimbursement based on policies limiting treatment to 
WHO functional class (FC) III patients. In the PATENT-1 study, the novel soluble 
guanylate cyclase stimulator riociguat significantly improved 6-minute walking 
distance (6MWD) and a range of secondary endpoints in patients with PAH. This 
subgroup analysis of PATENT-1 investigated the proportion of FC III/IV patients 
achieving threshold criteria. MethOds: PATENT-1 was a double-blind, randomized 
Phase III study in which patients with PAH received 12 weeks’ oral treatment with 
placebo, an individual titration of riociguat (up to 2.5 mg tid), or a capped titration 
of riociguat (up to 1.5 mg tid). Increase in 6MWD ≥ 40 m, 6MWD ≥ 380 m, cardiac 
index (CI) ≥ 2.5 L/min/m2, pulmonary vascular resistance (PVR) < 500 dyn·s·cm−5, 
mixed venous oxygen saturation (SvO2) ≥ 65%, FC I/II, absence of clinical worsen-
ing events, and NT-proBNP < 1800 pg/mL were chosen as positive response criteria 
based on studies showing their prognostic relevance at baseline and after targeted 
therapy. Results: At baseline, 241 patients were in FC III/IV (FC IV n= 4) across 
the three treatment groups, and similar proportions met selected criteria in the 
riociguat individual titration (n= 141) and placebo groups (n= 61). At Week 12/last 
visit, the proportion of patients fulfilling these criteria was higher in the riociguat 
individual titration group than the placebo group for all parameters: increase in 
6MWD ≥ 40m (44% vs 15%), 6MWD ≥ 380m (49% vs 36%), CI ≥ 2.5 L/min/m2 (75% vs 
43%), PVR < 500 dyn·s·cm−5 (52% vs 27%), SvO2 ≥ 65% (68% vs 35%), FC I/II (33% vs 
23%), absence of clinical worsening events (99% vs 90%), and NT-proBNP < 1800 pg/
mL (84% vs 64%). cOnclusiOns: In this population of predominantly FC III PAH 
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Objectives: Management with vitamin K antagonists (VKAs) has been an effec-
tive and cost-effective strategy for stroke prevention in atrial fibrillation (AF) but 
is associated with shortcomings. Novel oral anticoagulants (NOACs) were devel-
oped with the aims of no monitoring requirement and improved effectiveness 
and safety profiles. Economic evaluations require the comparison of all relevant 
options. However, there are no randomized controlled trials (RCTs) directly compar-
ing these agents. In such cases, indirect treatment comparison (ITC) can be used to 
synthesize indirect comparative evidence. Through ITC-based evidence synthesis, 
the cost-effectiveness of all available NOACs for stroke prevention in AF patients 
may be evaluated. MethOds: ITC models were based on RCTs data comparing 
dabigratran, rivaroxaban, or apixaban with VKA treatment. Relative effectiveness 
was estimated for stroke/systemic embolism, intracranial hemorrhage, myocar-
dial infarction, extracranial hemorrhage, and minor bleeding. A Markov model was 
developed using ITC-synthesized evidence with VKA as the baseline. Health utili-
ties were collected from international sources whereas costs and mortality data 
were extracted from Dutch sources. Univariate and probabilistic sensitivity analy-
ses (PSA) were conducted on the base-case incremental cost-effectiveness ratio 
(ICER). Results: The ICERs for dabigatran, apixaban, and rivaroxaban compared to 
VKA were € 12,146/QALY, € 12,488/QALY, and € 24,124/QALY, respectively. Sensitivity 
analysis using the upper and lower limits of the 95% confidence interval for abso-
lute stroke risk with VKA treatment resulted in ICERs that varied drastically from 
dominance for VKA to being dominated by all NOACs. This is likely due to the large 
uncertainty observed between the baseline risk profiles of the VKA arms in the 
three RCTs. The options with the highest probabilities of cost-effectiveness in PSA 
were VKA at thresholds under € 13,000/QALY and dabigatran or apixaban at thresh-
olds above this mark. cOnclusiOns: Dabigatran and apixaban were shown to be 
cost-effective options for AF patients in The Netherlands. However, these results 
were strongly influenced by uncertainty around stroke risk with VKA treatment.
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Objectives: Outcomes trials are currently underway to establish the effects of 
DPP-4 inhibitors on major adverse cardiovascular events (MACE), but to-date no 
major clinical trial has published results. Using simulations, we evaluated the 
effectiveness of DPP-4 inhibitors in preventing MACE in two populations with type 
2 diabetes, relative to the standard of care. MethOds: We used the Archimedes 
ARCHeS platform to simulate two clinical trials of virtual individuals with diag-
nosed type 2 diabetes (N= 11,000 each). The DPP-4 class was modeled with a meta-
analysis of HbA1c and weight change, pooling results from published trials. The 
study treatments were added-on to standard care. The first simulated trial examined 
subjects with elevated cardiovascular (CV) risk, based on established CV disease 
or multiple risk factors. The second considered individuals on metformin mono-
therapy with HbA1c ≥ 7%. We tracked changes in biomarkers and outcomes for 
20 years. Results: The DPP-4 class was associated with HbA1c drops of 0.66% 
[0.71% , 0.62% ] in the elevated CV risk population and 0.71% [0.75%,0.67%] in the 
metformin add-on population; and a weight drop of 0.14 [0.36,-0.07] kg in both 
cohorts. The biomarker benefits produced a relative risk (RR) for MACE at 5 years 
of 0.977 [0.968, 0.986] and 0.962 [0.949, 0.975] for the elevated CV risk population 
and metformin add-on population, respectively. The number needed to treat to 
prevent one occurrence of MACE at 5 years was 327 [233,550] in the elevated CV risk 
population. cOnclusiOns: Our simulated study suggests that DPP-4 inhibitors do 
not increase the risk of MACE relative to the standard of care in a population with 
elevated CV risk, and a representative diabetic metformin monotherapy population. 
This study provides insights on the long term benefits of DPP-4 inhibitors, and will 
support interpretation of the CV safety trial results likely to be published soon.
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Objectives: Given the absence of head-to-head studies, this review summarized 
indirect treatment comparison studies of oral anticoagulants (OACs) for the pre-
vention of stroke in patients with nonvalvular atrial fibrillation (NVAF). MethOds: 
Eligible English-language studies published up to May 31, 2013 were identified 
from electronic databases, Medline, EMBASE and Cochrane Library. Studies were 
included if the indirect comparison involved at least two OACs currently on the 
market with the common comparator warfarin. The search yielded ten pub-
lished studies and one in press study was obtained. Results: Eleven indirect 
comparison studies, based on data from three phase III (RE-LY, ROCKET-AF, and 
ARISTOTLE) and one phase II (PETRO) clinical trial, was reviewed. Six pairwise 
comparisons were reviewed across studies: any/all OACs vs. warfarin, apixaban 
vs. dabigatran 110mg, apixaban vs. dabigatran 150mg, apixaban vs. rivaroxaban, 
dabigatran 110mg vs. rivaroxaban, and dabigatran 110mg vs. rivaroxaban. OACs as 
a whole were found to have significantly better bleeding and efficacy endpoints 
when compared with warfarin. Apixaban and dabigatran 110mg were found to 
have significantly reduced risk of multiple bleeding endpoints when compared 
with rivaroxaban and dabigatran 150mg. Dabigatran 150mg was found to have 
significantly decreased risk of multiple efficacy endpoints when compared with 
rivaroxaban. Three studies compared discontinuation rates. Apixaban and rivar-
oxaban were found to have significantly lower discontinuation rates compared 
with both doses of dabigatran. Apixaban was also found to have a significantly 
lower discontinuation rate compared with rivaroxaban. cOnclusiOns: Apixaban, 
Hospital with suspected gynaecological malignancy and who fulfilled the inclu-
sion criteria were recruited for the study. All patients with BMI less than 35 received 
Tinzaparin (4500 IU) once daily injection while those with BMI more than 35 received a 
higher dose (7500 IU). Two days post surgery; venous blood samples were collected for 
anti-Xa analysis 4 hours post Tinzaparin injection. Results: The majority of patients 
received Tinzaparin of 4500 IU. The mean anti-Xa level in the malignant group was 
0.191 IU/ml while in the benign group the level was 0.1740 IU/ml. There was no dif-
ference between the two groups. In the malignant group, the number of cases with 
peak anti-Xa levels below 0.1IU/ml was slightly higher than in the benign group. One 
patient with malignant disease developed VTE, in the immediate postoperative period 
and showed a low peak anti-Xa level (0.06IU/ml). cOnclusiOns: The results of this 
study show that Tinzaparin prophylaxis provides adequate peak anti-Xa levels in the 
majority of gynae-oncology patients post surgery and is unlikely to be responsible 
for the high rates of VTE in cancer patients in the immediate post operative period. 
Larger studies are required to confirm this.
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Objectives: Pill splitting is a common problem in Hong Kong public hospitals for 
flexible dose adjustment and cost containment, especially for chronic diseases’ 
treatments such as hypertension, diabetes mellitus. The current study aimed 
to determine the importance of education on the proper way of pill splitting for 
elderly in Hong Kong by exploring their habits of pill splitting, evaluating their 
knowledge on pill cutting and investigating the impact of improper pill cutting 
habit. MethOds: Survey was conducted on elderly taking selected drugs require 
splitting (Metformin, Atenolol and Amlodipine) in 5 elderly centers. The survey 
focuses on habits and knowledge regarding pill cutting. Elderly subjects were asked 
to cut 3 pills that they were currently taking in their own ways. After proper educa-
tion, they were asked to cut another 3 pills with a pill cutter. The collected sample 
were then weighed and analyzed. The result was then compared with ideal value 
of half of the whole pill. Results: From the survey, 72% of the elderly have never 
received any education on pill cutting. Above half consider pill cutting troublesome. 
About half thought that all kinds of pills can be cut without affecting the expected 
effect. 80% cut pills for more than one dose each time, including 44% cut pills for 7 
days’ doses each time. From the experiment, the results of Metformin and Atenolol 
show that the cut drug samples’ weights deviate a lot from the ideal value (50% of 
the whole pill) before education. After education, the samples’ weights get closer 
to the ideal value. However, the result of Amlodipine does not show significant dif-
ference. cOnclusiOns: Education can improve the accuracy of dose in regimen 
require pill splitting. Elderly in Hong Kong do not receive enough education on the 
proper way of pill splitting from the health care giver.
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Objectives: European guidelines recommend statins as first-line treatment for 
elevated cholesterol in patients at high cardiovascular (CV) risk; however, many 
patients do not attain guideline-recommended goals on statin monotherapy. As 
atorvastatin is now generically-available and its use is likely to increase, we exam-
ined recommended total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C) levels in high-risk patients treated with atorvastatin monotherapy in the 
UK. MethOds: In this retrospective UK general practice database study, included 
were patients with a prescription for atorvastatin monotherapy (IndexRx) between 
November 30, 2008-November 30, 30, 2011, who had evidence of coronary heart dis-
ease (CHD), atherosclerotic vascular disease (AVD), diabetes mellitus (DM), or familial 
hypercholesterolemia, ≥ 1 TC and LDL-C measurement 3-12 months post-IndexRx, 
and an atorvastatin prescription (to determine the daily dose) within 45 days of lipid 
measurements. Endpoints included proportions of patients (overall and by dose) 
below guideline-specific thresholds: TC< 5.0, TC< 4.0, and for patients with CHD/
AVD+DM, TC< 4.0 or LDL< 2.0 mmol/L. Results: Of 2999 high-risk patients (60.2% 
males, mean age 67.9 years [SD 10.6]) meeting selection criteria, 23.9, 28.2, 36.2, and 
11.6% received prescriptions for 10-mg, 20-mg, 40-mg, and 80-mg atorvastatin, respec-
tively. Further, 27.6% of patients were newly initiated with atorvastatin monotherapy 
at index date. Overall, mean follow-up TC was 4.08 (SD 0.80) and LDL-C was 2.08 (SD 
0.65) mmol/L. The proportion of patients with TC< 5.0 and < 4.0 mmol/L was 88.8% 
and 45.8%, respectively. For those with CHD/AVD+DM, 63.7% had TC< 4.0 or LDL-C< 2.0 
mmol/L. Generally, more patients were below lipid thresholds with higher atorvastatin 
doses. cOnclusiOns: In UK patients at high CV risk, a substantial proportion did 
not achieve guideline-recommended lipid levels. Less than half of patients achieved 
TC< 4.0 mmol/L, and only two-thirds of patients with CHD/AVD+DM were below rec-
ommended levels for either TC or LDL-C. More effective lipid-lowering strategies may 
be needed to achieve optimal TC and LDL-C levels in high-risk patients.
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